BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 10520703)

  • 1. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.
    Schulte M; Brecht-Krauss D; Werner M; Hartwig E; Sarkar MR; Keppler P; Kotzerke J; Guhlmann A; Delling G; Reske SN
    J Nucl Med; 1999 Oct; 40(10):1637-43. PubMed ID: 10520703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis.
    Franzius C; Sciuk J; Brinkschmidt C; Jürgens H; Schober O
    Clin Nucl Med; 2000 Nov; 25(11):874-81. PubMed ID: 11079583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET.
    Ye Z; Zhu J; Tian M; Zhang H; Zhan H; Zhao C; Yang D; Li W; Lin N
    Ann Nucl Med; 2008 Jul; 22(6):475-80. PubMed ID: 18670853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
    Hamada K; Tomita Y; Inoue A; Fujimoto T; Hashimoto N; Myoui A; Yoshikawa H; Hatazawa J
    Ann Nucl Med; 2009 Jan; 23(1):89-95. PubMed ID: 19205843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
    Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
    J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis.
    Bajpai J; Kumar R; Sreenivas V; Sharma MC; Khan SA; Rastogi S; Malhotra A; Gamnagatti S; Kumar R; Safaya R; Bakhshi S
    J Pediatr Hematol Oncol; 2011 Oct; 33(7):e271-8. PubMed ID: 22193290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.
    Hawkins DS; Rajendran JG; Conrad EU; Bruckner JD; Eary JF
    Cancer; 2002 Jun; 94(12):3277-84. PubMed ID: 12115361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
    Cheon GJ; Kim MS; Lee JA; Lee SY; Cho WH; Song WS; Koh JS; Yoo JY; Oh DH; Shin DS; Jeon DG
    J Nucl Med; 2009 Sep; 50(9):1435-40. PubMed ID: 19690035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma.
    Huang TL; Liu RS; Chen TH; Chen WY; Hsu HC; Hsu YC
    J Chin Med Assoc; 2006 Aug; 69(8):372-6. PubMed ID: 16970273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential ¹⁸F-FDG PET/CT and MRI.
    Byun BH; Kong CB; Lim I; Kim BI; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1553-62. PubMed ID: 24652233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-to-background ratio to predict response to chemotherapy of osteosarcoma better than standard uptake values.
    He JP; Hao Y; Li M; Wang J; Guo FJ
    Orthop Surg; 2014 May; 6(2):145-53. PubMed ID: 24890297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can pretreatment
    Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
    Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors.
    Benz MR; Evilevitch V; Allen-Auerbach MS; Eilber FC; Phelps ME; Czernin J; Weber WA
    J Nucl Med; 2008 Jul; 49(7):1038-46. PubMed ID: 18552153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
    Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.
    Gaston LL; Di Bella C; Slavin J; Hicks RJ; Choong PF
    Skeletal Radiol; 2011 Aug; 40(8):1007-15. PubMed ID: 21298431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.
    Im HJ; Kim TS; Park SY; Min HS; Kim JH; Kang HG; Park SE; Kwon MM; Yoon JH; Park HJ; Kim SK; Park BK
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):39-49. PubMed ID: 21953008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma.
    Franzius C; Bielack S; Flege S; Sciuk J; Jürgens H; Schober O
    J Nucl Med; 2002 Aug; 43(8):1012-7. PubMed ID: 12163625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of thallium-201 scintigraphy in assessment of neoadjuvant chemotherapy for osteosarcoma].
    Huang ZK; Lou C; Fang XQ
    Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):769-72. PubMed ID: 20021831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.
    Kong CB; Byun BH; Lim I; Choi CW; Lim SM; Song WS; Cho WH; Jeon DG; Koh JS; Yoo JY; Lee SY
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):728-36. PubMed ID: 23361860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.